Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration (TARMAC-1)

Centre Hospitalier Universitaire de Nice

Status

Completed

Conditions

Age Related Macular Degeneration

Treatments

Procedure: Aqueous humor samples collection

Study type

Interventional

Funder types

Other

Identifiers

NCT03630562

17-PP-18

Details and patient eligibility

About

Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines.

The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age > 18 years
Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment.
Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months
Signature of informed consent
Affiliation to the French social security system

Exclusion criteria

Pregnant or nursing patient (a urinary pregnancy test will be performed)
Systemic treatment with anti-VEGF
Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye.
Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis.
Diabetes Mellitus
High Myopia
Simultaneous participation in another clinical research protocol in exudative AMD
Person under guardianship, under curatorship, deprived of liberty